SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2004. CA Cancer J Clin. 2005; 55: 1030.
  • 2
    Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000; 355: 14911498.
  • 3
    Pienta K, Smith D. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005; 55: 300318.
  • 4
    Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993; 71: 10981109.
  • 5
    Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14: 17561764.
  • 6
    Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17: 25062513.
  • 7
    Fizazi K, Sikes CR, Kim J, et al. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004; 24: 28972903.
  • 8
    Picus J, Schultz M, Cochrane J. A phase II trial of docetaxel in patients with hormone-refractory prostate cancer (HRPC): long term results. Proc Am Soc Clin Oncol. 1999; 18: 1206. Abstract.
  • 9
    Friedland D, Cohen J, Miller RJr., et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol. 1999; 26( Suppl 17): 1923.
  • 10
    Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001; 28( Suppl 15): 815.
  • 11
    Gravis G, Bladou F, Salem N, et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer. 2003; 98: 16271634.
  • 12
    Ferrero JM, Foa C, Thezenas S, et al. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology. 2004; 66: 281287.
  • 13
    Kosty MP, Ferreira A, Bryntesen T. Weekly docetaxel and low-dose estramustine phosphate in hormone-refractory prostate cancer: a phase II study. Proc Am Soc Clin Oncol. 2001; 20: 2360. Abstract.
  • 14
    Tiersten AD, Nelsen C, Talbot S, et al. A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003; 97: 537544.
  • 15
    Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 2002; 94: 14571465.
  • 16
    Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001; 19: 25092516.
  • 17
    Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 15131520.
  • 18
    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 15021512.
  • 19
    Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005; 23: 33433351.
  • 20
    Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998; 4: 10131019.
  • 21
    O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20: 28122823.
  • 22
    Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 34613467.
  • 23
    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 24
    Aaronson NK, Ahmedzai S, Bergman B, et al. European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365376.
  • 25
    Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996; 5: 299314.
  • 26
    Haldar S, Chintipalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996; 56: 12531255.
  • 27
    Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res. 1997; 57: 229233.
  • 28
    Roth BJ, Yeap BY, Wilding GW, et al. Taxol in advanced, hormone refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993: 72: 24572460.
  • 29
    Berry WR, Hathorn JW, Dakhil SR, et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer. 2004; 3: 104111.
  • 30
    Trivedi C, Redman B, Flaherty LE, et al. Weekly 1-hour infusion paclitaxel: clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer. 2000; 89: 431436.
  • 31
    Eymard JC, Joly F, Priou F, et al. Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): a final report. Proc Am Soc Clin Oncol. 2004; 23: 4603. Abstract.
  • 32
    Vaughn DJ, Brown AWJr., Harker WG, et al. Multicenter phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. Cancer. 2004; 100: 746750.
  • 33
    Hudes GR, Manola J, Conroy J, et al. Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): a trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol. 2001; 20: 697. Abstract.
  • 34
    Hainsworth JD, Burris HA3rd, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998; 16: 21642168.
  • 35
    Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004; 22: 25322539.
  • 36
    Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003; 21: 123128.
  • 37
    Beer TM, Ryan CW, Venner PM, et al. Interim results from ASCENT: a double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol. 2005; 24: 4516. Abstract.